Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Merit Medical Systems, Inc is a medical instruments & supplies business based in the US. Merit Medical Systems shares (MMSI) are listed on the NASDAQ and all prices are listed in US Dollars. Merit Medical Systems employs 6,000 staff and has a trailing 12-month revenue of around USD$962.9 million.
|52-week range||USD$19.5 - USD$50.38|
|50-day moving average||USD$45.5409|
|200-day moving average||USD$43.3361|
|Wall St. target price||USD$51.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.332|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Merit Medical Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merit Medical Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merit Medical Systems's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 379x. In other words, Merit Medical Systems shares trade at around 379x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merit Medical Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4764. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merit Medical Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merit Medical Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$136.2 million.
The EBITDA is a measure of a Merit Medical Systems's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$962.9 million|
|Operating margin TTM||4.37%|
|Gross profit TTM||USD$432.4 million|
|Return on assets TTM||1.53%|
|Return on equity TTM||-3.17%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
There are currently 3.5 million Merit Medical Systems shares held short by investors – that's known as Merit Medical Systems's "short interest". This figure is 10.3% down from 3.9 million last month.
There are a few different ways that this level of interest in shorting Merit Medical Systems shares can be evaluated.
Merit Medical Systems's "short interest ratio" (SIR) is the quantity of Merit Medical Systems shares currently shorted divided by the average quantity of Merit Medical Systems shares traded daily (recently around 488348). Merit Medical Systems's SIR currently stands at 7.25. In other words for every 100,000 Merit Medical Systems shares traded daily on the market, roughly 7250 shares are currently held short.
However Merit Medical Systems's short interest can also be evaluated against the total number of Merit Medical Systems shares, or, against the total number of tradable Merit Medical Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merit Medical Systems's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Merit Medical Systems shares in existence, roughly 60 shares are currently held short) or 0.089% of the tradable shares (for every 100,000 tradable Merit Medical Systems shares, roughly 89 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Merit Medical Systems.
Find out more about how you can short Merit Medical Systems stock.
We're not expecting Merit Medical Systems to pay a dividend over the next 12 months.
Merit Medical Systems's shares were split on a 5:4 basis on 6 May 2011. So if you had owned 4 shares the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Merit Medical Systems shares – just the quantity. However, indirectly, the new 20% lower share price could have impacted the market appetite for Merit Medical Systems shares which in turn could have impacted Merit Medical Systems's share price.
Over the last 12 months, Merit Medical Systems's shares have ranged in value from as little as $19.5 up to $50.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merit Medical Systems's is 1.0987. This would suggest that Merit Medical Systems's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.